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Introduction: Endovascular aneurysm repair (EVAR) with aortouniiliac prostheses extends the morphologic range of
aneurysms that can be treated and is potentially a more rapid and simple operation than bifurcated endovascular repair.
It may, however, be limited by durability of the femorofemoral extra-anatomic bypass graft required to revascularize the
contralateral lower limb. Previous studies of femorofemoral bypass grafts were performed almost exclusively in patients
with occlusive disease. An 8-year single center experience with use of the femorofemoral bypass graft in aneurysmal
disease is reported.
Methods: All patients undergoing EVAR with an aortouniiliac endovascular stent graft over eight years (1994-2002) at a
single institution were included in a retrospective study. Patient data were collected from a prospectively maintained local
endovascular database. All patients gave informed consent and were part of an endovascular program approved by the
local ethics committee.
Results: Over the 8 years, 231 patients underwent EVAR with an aortouniiliac endovascular stent-graft. Median
follow-up was 22 months. Localized wound complications were observed in 25 patients (11%). Cumulative 3-year
patency rate for the femorofemoral bypass graft was 91%. At the end of 5 years 83% of grafts remained patent.
Conclusions: The femorofemoral bypass graft used during EVAR with aortouniliac stent grafts offers encouraging
medium and long-term patency. When graft occlusion occurs, it is usually directly attributable to inadequate inflow from
the endovascular stent graft itself or to endoluminal damage of the external iliac artery. Awareness and early detection of
stent-graft distortion or complications in the external iliac artery may result in improved patency rates. (J Vasc Surg
2003;38:498-503.)
The bifurcated configuration has gained popularity in
endovascular management of abdominal aortic aneurysm
(AAA) because it appears more anatomic than the uniiliac
approach. Bifurcated stent grafts are, however, suitable in
fewer patients and are more difficult and time-consuming
to deploy.1,2 An integral part of endovascular abdominal
aortic aneurysm repair (EVAR) using an aortouniiliac en-
doprosthesis is the femorofemoral bypass graft. It has been
argued that the additional extra-anatomic prosthetic bypass
graft required for the uniiliac approach potentially increases
the number of complications and limits durability of the
aneurysm repair.
In occlusive arterial disease the patency of femorofemo-
ral bypass grafts has proved inferior to that with aortob-
ifemoral reconstruction.3 However, early reports of the use
of femorofemoral bypass grafts in aneurysmal disease have
been more encouraging.4 We report the medium and long-
term durability of femorofemoral bypass after EVAR with
aortouniiliac stent grafts.
METHODS
All patients undergoing EVAR with aortouniiliac pros-
theses over 8 years (1994-2002) at a single institution were
included in the study.
A variety of endovascular grafts were used, including
the Chuter, Nottingham-Malmo, and Zenith (Cook Eu-
rope, Bjaerskov, Denmark). All endovascular stent grafts
were manufactured of Dacron and supported by Gianturco
stainless steel self-expandable stents. Details of these de-
vices have been described.5-7
Aortouniiliac prostheses were used routinely from
1994 until 1998, with the exception of the early bifurcated
Chuter prostheses. In 1998 a commercially produced bi-
furcated endograft (Zenith) became available for use in this
institution. Since that time, all anatomically suitable pa-
tients have received bifurcated endoprostheses, with the
exception of patients with ruptured aneurysm or adverse
anatomy of one or both common iliac arteries (eg, length
35 mm; diameter22 mm). The endograft was routinely
deployed in the common iliac artery. When the common
iliac artery did not present an adequate landing zone,
principally in the presence of a common iliac artery aneu-
rysm, or when thrombosis of a large internal iliac artery
aneurysm was intended, an external iliac artery landing site
was used.
Femorofemoral bypass grafting was standardized in all
patients. Patients received a single intravenous dose of
prophylactic antibiotics at induction of anesthesia, and
were prepared with a chlorhexidene antiseptic solution.
The anastomoses were made to the common femoral arter-
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ies, and the graft was tunneled superficially, anterior to the
rectus sheath. Two graft materials were used: polyester
(Dacron) and polytetrafluoroethylene (PTFE), each of ei-
ther 8 or 10 mm diameter. The type and diameter of graft
varied according to surgeon preference and patient charac-
teristics. Anticoagulation therapy was not routinely admin-
istered after graft insertion.
Preoperative, intraoperative, and perioperative data
were collected prospectively for all patients and stored in a
database. Superficial wound infection, seroma, and lym-
phocele were defined in an early report by our group.4 Data
are presented according to the guidelines suggested by the
North American Society for Vascular Surgery for reports of
lower extremity ischemia.8
After discharge, patients were entered in an EVAR
surveillance program, which included clinical review and
computed tomography of the abdominal aorta twice in the
first postoperative year and yearly thereafter.
RESULTS
Two hundred thirty-one patients underwent EVAR
with aortouniiliac endografts. Two hundred seven of these
patients were men. Mean age for the entire group was 72
years (range, 47-88 years). Median aneurysm diameter was
7.1 cm (range, 5.1-12 cm). Mean duration of follow-up
was 29 months (median, 22 months). Sixty-nine patients
were followed up for 3 years or longer. Overall periopera-
tive mortality was 15% (n  34). Cumulative patency rate
was 91% at 3 years and 83% at 5 years (Table I; Figure).
Most crossover grafts (n 170) were made of Dacron.
Nineteen (8%) patients received 8-mm-diameter grafts; the
remainder received 10-mm-diameter grafts. Mean duration
of surgery was 165 56 minutes (range, 60-540 minutes).
However, duration of surgery was significantly longer in
patients in whom graft infection subsequently developed
compared with patients without graft infection (P  .03,
Mann-Whitney U test; Table II).
Localized perioperative wound complications occurred
in 25 patients (11%): groin hematoma in 9 patients (4%),
seroma in 6 patients (3%), and superficial wound infection
in 10 patients (4%). Graft sepsis developed in two patients
developed after visceral damage incurred on tunneling the
prosthetic graft. One of these patients had an unrecognized
incisional hernia from previous laparotomy, and an entero-
cutaneous fistula subsequently developed. In the other
patient serous fluid was discharged at tunneling of the
prosthetic graft from one groin to the other. This patient
had previously undergone laparotomy to treat intra-ab-
dominal abscess.
Later infections were attributed to blood-borne infec-
tion. In one patient this was due to generalized abdominal
sepsis after unrelated abdominal surgery performed many
months later; in the other patients infection was suspected
earlier in the postoperative course because of unexplained
postoperative pyrexia, discharge from a groin wound, and
formation of a wound sinus, which did not resolve despite a
prolonged course of antibiotic therapy.
Graft infection was associated with high morbidity and
mortality. Seven infected grafts required removal and im-
plantation of another extra-anatomic bypass graft. Three
patients were managed without operation, because of med-
ical comorbidity in one patient, rendering that patient unfit
for further surgical intervention, and presence of low-grade
infection that responded to intermittent courses of antibi-
Kaplan-Meier analysis of femorofemoral graft patency.
Table I. Life table analysis of femorofemoral bypass graft patency after EVAR with aortouniiliac stent
Interval
(mo)
No. of grafts
at risk at start
No. of
failed grafts
Loss to
duration
Loss to
follow-up
Loss
to death
Interval
patency rate
Cumulative
patency rate (%)
Standard
error (%)
0-1 231 5 9 0 32 0.98 100 0
1-3 185 5 5 0 11 0.97 98 1.0
3-6 164 1 7 0 7 0.99 95 1.7
6-12 151 1 9 4 7 0.99 94 1.9
12-24 130 2 18 6 15 0.98 93 2.2
24-36 89 0 10 4 6 1.00 91 2.9
36-48 69 0 14 4 5 1.00 91 3.3
48-60 46 1 23 0 1 0.97 91 4.0
60-72 21 1 7 0 1 0.94 88 6.7
72-84 12 0 6 0 2 1.00 83 9.9
84-96 4 0 4 0 0 1.00 83 17.1
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 3 Hinchliffe et al 499
otic therapy in the others. Another 3 of the 10 patients with
graft infection subsequently died of related complications.
Limb salvage was attained in all patients who underwent
secondary procedures (Table III).
Despite crossover graft sepsis, there was no clinical or
radiologic evidence of direct or indirect contamination of
the aortouniiliac prosthesis in any patient.
Of the 10 patients with femorofemoral bypass graft
occlusion, 4 patients had symptomatic preexisting periph-
eral arterial occlusive disease (Table IV). None of these
patients had critical ischemia. In all 10 patients with femo-
rofemoral bypass occlusion there was coexisting occlusion
of the endovascular aortic stent graft. The iliac limb of the
endograft was deployed in the external iliac artery in 5 of
the 10 patients with grafts that subsequently became oc-
cluded.
Of the other five patients in whom bypass grafts became
occluded, four patients had an identifiable precipitating
factor, ie, kinking of the main body or iliac limb of the
endograft, resulting in poor femorofemoral bypass inflow.
Two grafts occluded early, despite intraoperative treatment
of kinks with a Wallstent, and two occluded later as a result
of caudal migration of the endograft.
Restoration of graft patency was possible in only two
patients. Both occlusions occurred early in the periopera-
tive period and were managed with thrombectomy and
insertion of Wallstents to straighten kinks in the endograft.
Five patients received an extra-anatomic axillobifemoral
bypass graft, and one patient underwent open aneurysm
repair.
As a result of graft occlusion, there were two lower limb
amputations and two deaths. Two patients were managed
nonoperatively, one because of self-limiting claudication
and the other because of advanced malignant disease.
DISCUSSION
The aortouniiliac configuration was adopted early in
the evolution of endovascular aneurysm repair, because of
the ability to load the stent graft onto a smaller sheath,
combined with ease of manufacture. Subsequently uniiliac
endografts were demonstrated to accommodate a greater
number of aneurysms than either aortoaortic or bifurcated
designs, principally because of their ability to exclude con-
comitant unilateral common iliac artery aneurysms.1
When the aortouniiliac system was first introduced,
concerns were raised about durability of the extra-anatomic
femorofemoral bypass. It was believed the additional graft
would add to the morbidity of the procedure and adversely
affect long-term outcome of the uniiliac configuration.
Parallels were drawn with use of femorofemoral bypass
grafting in iliac occlusive disease. In occlusive disease extra-
anatomic bypass is generally accepted to carry a patency rate
inferior to that with aortobifemoral reconstruction,3 al-
though some centers have reported 6-year patency rates in
excess of 90% for femorofemoral bypass.9
However, early reports of femorofemoral bypass graft-
ing in aneurysmal disease were encouraging, and suggested
that femorofemoral bypass grafting in aneurysmal disease
was associated with satisfactory patency rates and low mor-
bidity. At a median follow-up of 7 months, the graft occlu-
sion rate was 0.7%. In only 3% of patients was a secondary
intervention required to treat a complication arising from
the femorofemoral crossover graft.4
Local wound complications, eg, hematoma, seroma,
and superficial wound infection, are not necessarily related
to the femorofemoral bypass graft and can just as easily be
related to dissection of the common femoral artery. Bifur-
cated devices may expect to produce in the region of 8.4%
local groin complications, similar to the 11% experienced in
our study.10
The potential for direct contamination and infection of
the prosthetic graft is related to duration of operative
procedure, and is likely to be greater with this configuration
than with bifurcated devices. It is interesting that infection
of femorofemoral bypass grafts has not been associated with
direct or indirect spread of infection to the endovascular
graft. Commonly reported 3-year patency rates for femo-
rofemoral bypass grafting in occlusive disease range from
60% to 69%,11,12 whereas the cumulative patency rate in
the current study was 91% at 3 years and 83% at 5 years,
which compares with the best outcomes reported for femo-
rofemoral and aortobifemoral grafts.3,9
The results of this study suggest that patency of femo-
rofemoral bypass grafting to treat aneurysmal disease is
favorable when compared with occlusive disease. Similarly,
aortobifemoral grafting is associated with a better progno-
sis when performed to treat aneurysmal disease compared
with occlusive disease.13 Indeed, it has been clearly dem-
onstrated that early and late postoperative failure of both
extra-anatomic and aortofemoral grafts is related to the
presence of adequate runoff vessels.14-16
Table II. Comparison of patients with femorofemoral
graft patency
Total
(n  231)
No
complication
(n  211)
Occlusion
(n  10)
Infection
(n  10)
POAD* 49 43 5 2
RAAA 30 29 0 1
Mean duration
of operation
( SD)†
165 (56) 164 (57) 167 (39) 191 (45)
Diabetes mellitus* 9 6 1 3
Renal impairment 39 36 1 2
Graft material
Dacron 170 158 6 6
PTFE 61 53 4 4
Graft material
10 mm 212 192 11 9
8 mm 19 19 0 0
POAD, Peripheral artery occlusive disease; RAAA, ruptured abdominal
aortic aneurysm; PTFE, polytetrafluoroethylene.
*One patient with occlusion and infection.
†Duration of operation longer in patients with subsequent graft infection
(P  .03).
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There was no relationship between incidence of com-
plications and type of graft material used, which corre-
sponds to findings of a recent large prospective randomized
study of Dacron and PTFE in aortofemoral bypass grafts.17
All femorofemoral bypass occlusion was associated with
occlusion of the endovascular stent graft. In a report of the
failure of endovascular aortic limbs, there appeared to be
improved patency in aortouniiliac grafts (97%) at 18
months compared with bifurcated grafts (90%); however,
the results did not reach statistical significance.18 Rehring
et al19 reported a 98% primary patency rate over a similar
time period (15.8 months) in patients with aortouniiliac
endografts. Of interest, the one case of graft occlusion in
the latter study occurred after iatrogenic dissection of the
external iliac artery.
In a recent study of patients with unsupported en-
dograft limbs, 24% developed endograft limb stenosis or
occlusion during a mean follow-up of 16 months.20 Fully
stented endograft limbs appear to offer improved patency
over unsupported limbs, probably related to their kink
resistance.18 However, the current range of fully stented
designs remain at risk of kinking in tortuous arteries. The
risk remains over the long term because of alterations in
stent position secondary to migration or possibly longitu-
dinal shrinkage of the aneurysm sac. Bifurcated endografts
may be susceptible to occlusion of one iliac limb when both
limbs compete for space in the presence of a narrow distal
(waisted) aorta, which may compress one or other limb.
Graft limb thrombosis was reported with bifurcated stent-
graft systems: 7% at a mean of 11 months of follow-up by
Stelter et al21 and 5% at 7 months of follow-up by Faries et
al.10
In the present study, inflow problems leading to early
graft occlusion were due to either instrumentation damage
of the external iliac artery, a low flow state created by an
unrecognized kink in the endograft, or deployment of the
endograft in a narrow external iliac artery.
Recent endograft designs have improved sheaths to try
to reduce damage to the arterial intima. Deployment of
endografts in narrow external iliac arteries should also be
Table III. Demographic data for patients with femorofemoral graft infection
Patient Risk factor Clinical presentation
Time after
operation Management Outcome
A Laparotomy to treat unrelated
abdominal sepsis
Perigraft collection
and sepsis
71 mo Graft removal and
revision
Successful
B Previous laparotomy because of
unrelated abdominal sepsis;
intraoperative Wallstent
because of EVG occlusion
Localized groin
sepsis
2 wk Removal of
femorofemoral
bypass graft and
insertion of axillo
bifemoral bypass
graft
Occlusion of one
limb of
axillobifemoral
bypass graft
C IDDM, groin hematoma MRSA septicemia,
graft dehiscence
2 wk Graft excision and
antibiotic-soaked
graft inserted
Died of MI on day
30
D* Heart failure, sepsis Ischemic but viable
lower limbs
1 mo Axillobifemoral
bypass graft
Perioperative death
due to MI
E Postoperative superficial groin
wound infection
Early groin infection
resolved with
antibiotics; sinus
subsequently
developed
6 mo Conservative;
repeated courses
of antibiotics, as
necessary
Alive; graft patent at
42 mo
F Ruptured AAA Sepsis
enterocutaneous
fistula
1 wk Laparotomy, repair
of SB and
revision of
crossover graft
Perioperative death
from multiple
organ failure
G Unexplained postoperative fever Perigraft collection,
pseudoaneurysm
23 mo Graft revision to
silver graft
Alive; graft patent at
32 mo
H Unrecognised periampullary
malignancy and low-grade
DIC; secondary procedure to
treat wound hematomas
Localized groin
sepsis
2 wk Conservative
because of
advanced
malignancy
Died of disseminated
malignancy (2 mo)
I* Second procedure perioperatively
to treat occlusion; BKA due to
graft occlusion
Discharging wound
sinus
23 mo Conservative,
antibiotics
Alive; graft patent at
15 mo
J Long procedure requiring
conversion from bifurcated to
uniiliac EVG
Discharging wound 2 mo Graft removed and
replaced with
extra-anatomic
vein graft
Alive; graft patent at
9 mo
EVG, Endovascular graft; IDDM, insulin-dependent diabetes mellitus; MRSA, methicillin-resistant Staphylococcus aureus; MI, myocardial infarction; SB, small
bowel; DIC, disseminated intravascular coagulation; BKA, below-knee amputation.
*Patient also included in Table IV.
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averted, as suggested by Carroccio et al22 in their study of
bifurcated endografts. Occlusion of endografts extending
into the external iliac arteries may be related to a number of
factors, including gross oversizing of grafts, with inade-
quate deployment or crowding of graft material in the
relatively narrow external iliac artery, low flow within a
narrow external iliac artery, or kinking of the endograft at
the angulation between the common and external iliac
arteries.
Late occlusions were primarily associated with caudal
migration and endograft kinking.
In the present study, occlusion of the femorofemoral
bypass graft was associated with major morbidity. Of the
eight patients treated at surgery, major amputation was
required in two patients and another two patients died
as a result of attempted revascularization. Lower limb
salvage was possible in four of eight patients. In com-
parison with other studies of femorofemoral crossover
occlusion, mortality appears high and is probably related
to concomitant aortic occlusion, which occurred in the
patients in this study, and associated medical comorbidity,
for which many of these patients underwent endovascular
procedures.
The studies of iliac limb occlusion in bifurcated en-
dografts suggests that fewer patients present with critical
ischemia, which may account for the improved outcome. In
one study of bifurcated endograft limb occlusions only 8%
of patients had rest pain, although 69% subsequently re-
quired some form of revascularization.22 All revasculariza-
tion procedures were successful in preventing limb loss, and
there were no perioperative deaths. Improved outcome
may also be related to preservation of collateral pathways
via the iliac arteries. Indeed, three amputations were re-
quired in 22 patients (14%) undergoing femorofemoral
Table IV. Demographic data for patients with femorofemoral graft occlusion
Patient
Perioperative and postoperative
risk factors
Clinical
presentation
Time after
operation Management Outcome
1 Late EVG migration and
kinking
Short-distance
claudication
56 mo Axillobifemoral bypass
graft
Reocclusion required
axillobifemoral
bypass revision
2 Aorto-aortic EVG converted to
AUI intraoperatively because
of distal endoleak.
Critical ischemia
post-
cholecystectomy
2 mo Axillobifemoral bypass
graft
Above-knee amputation
Intra-op Wallstent for EVG
angulation
3 EVG deployed in right EIA
(right CIA aneurysm);
intraoperative Wallstent for
EVG angulation; late EVG
migration
Bilateral thigh
claudication
15 mo No intervention Stable claudication
4 Intimal tear (dissection) of EIA Critical ischemia 2 mo Conversion to open
repair
Successful reperfusion
5 PAOD (previous aortoiliac
endarterectomy), inguinal
lymphadenopathy
(lymphoma), EVG deployed
in EIA
Critical ischemia 2 wk Insertion of
Wallstents; CIA and
EIA encased in
tumor
Successful reperfusion
6 Carcinoma of unknown origin Critical ischemia 9 mo Conservative
nonoperative
treatment
Died of metastatic
carcinoma, bronchus
at 13 mo
7 PAOD, groin wound infection;
EVG intentionally deployed
in EIA, IIA occluded (CIA
aneurysms); right EIA
dissection
Short-distance
claudication
2 mo Axillobifemoral bypass
graft
Successful reperfusion
8 Previous pelvic DXT; wound
infection; EVG deployed
intentionally in EIA
Critical ischemia 5 mo Axillobifemoral bypass
graft
Axillobifemoral
occlusion; died
9* PAOD, sepsis Critical ischemia 1 mo Axillobifemoral bypass
graft
Perioperative death
10* PAOD (claudication due to
occluded popliteal
aneurysms); right CFA
aneurysm; EVG deployed
intentionally in EIA to
thrombose IIA aneurysm
Critical ischemia 2 d Graft thrombectomy
and Wallstent
insertion
Below-knee
amputation; late graft
infection at 13 mo
EVG, Endovascular graft; AUI, aortouniiliac; EIA, external iliac artery; CIA, common iliac artery; PAOD, peripheral arterial occlusive disease; IIA, internal iliac
artery; CFA, common femoral artery; DXT, radiotherapy.
*Patient also included in Table III.
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bypass grafting after conventional aortobifemoral graft
limb occlusion.23
Endovascular management of graft occlusion may be a
more attractive technique because of patient comorbidity,
but was possible in only two patients. In both patients the
technique was performed early in the postoperative period
because of occlusion in association with endograft limb
kinking. Graft patency was successfully restored in both
patients, although amputation was required in one patient
because of worsening of preexisting distal ischemia. Others
have used endovascular techniques to good effect in man-
agement of iliac limb occlusion of bifurcated endovascular
grafts, thus preventing the requirement for femorofemoral
bypass grafting, although at the risk of limb separation in
modular grafts.24
In conclusion, perioperative morbidity associated with
aortouniiliac endovascular aneurysm repair and femoro-
femoral crossover is similar to that reported with bifurcated
endovascular stent grafts.
Patency rate with femorofemoral bypass grafting is
generally better than that reported for occlusive disease and
comparable to that with open aortobifemoral or bifurcated
endovascular repair of abdominal aortic aneurysm over the
medium and long term.
In contrast to their use in iliac occlusive disease, the
mode of graft failure appears to be related to problems of
inflow rather than runoff. Specifically, patency of the femo-
rofemoral bypass graft is ultimately related to performance
of the aortouniiliac endograft.
Occlusion of the crossover graft may be prevented in
the perioperative period with particular attention to avert
damage to the donor external iliac artery or common
femoral artery from arterial sheaths and guidewires, by
preventing or treating kinking of iliac limbs, and by not
deploying endografts in narrow external iliac arteries.
Long-term patency is more likely to be assured with regular
endograft surveillance to monitor stent-graft distortion.
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